This is not the first time that HDAC is designated as a good target for synovial sarcoma and in the past, other HDAC inhibitors trials have been listed in the clinical trial database, yet all seem to end up in the "unknown status" eventually with no result, either bad or good. I am wondering what's going on behind the doors...
Are you able to provide a copy of the article in the first link? When I click on it, it's a pay to view site...
Also, is anyone on any of these trials? Particularly the one using romidepsin? I'm trying to get any information of it working in synovial sarcoma... From what I've been able to read, it seems like these drugs could be very promising.
The article must have been free at one point for me to put the link here. Unfortunately, I don't have it on my computer :-( May be, Mimi Olsson can get it. Ask her:
I haven't found one patient with synovial sarcoma who was able to participate in the trials. I have results of 2 vorinostat trials in children but no synovial sarcoma patients in those. I've known of 2 synovial sarcoma patients who tried to get into HDAC inhibitor trials and none were able to.